Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
EMD Serono
Eli Lilly and Company
Kivu Bioscience Inc.
AstraZeneca
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
National Cancer Institute (NCI)
The New York Proton Center
Association Francaise pour la Recherche Thermale
Jazz Pharmaceuticals
Fate Therapeutics
DualityBio Inc.
Conjupro Biotherapeutics, Inc.
Eastern Cooperative Oncology Group
International Agency for Research on Cancer
The Second Affiliated Hospital of Hainan Medical University
GlaxoSmithKline
Terremoto Biosciences Inc.
Stanford University
Ensem Therapeutics
Varian, a Siemens Healthineers Company
PMV Pharmaceuticals, Inc
FindCure Biosciences (ZhongShan) Co., Ltd.
Hoffmann-La Roche
University of Chicago
University of California, Irvine
Eli Lilly and Company
ViroMissile, Inc.
University Health Network, Toronto
Kaiser Permanente
Duke University
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Poseida Therapeutics, Inc.
IDEAYA Biosciences
Baylor College of Medicine
University of Colorado, Denver
MacroGenics
Avacta Life Sciences Ltd
SystImmune Inc.
Daiichi Sankyo
SN BioScience
Takeda
Oscotec Inc.
Kidney Cancer Research Bureau
Second Life Therapeutics
Fusion Pharmaceuticals Inc.